Shearman & Sterling represented BofA Merrill Lynch, Barclays, Deutsche-Bank and J.P. Morgan as joint book-running managers and representatives of the several underwriters in connection with Amgen Inc.’s registered offering of €2 billion of investment-grade notes, consisting of €1,250,000,000 of 1.250% senior notes due 2022 and €750,000,000 of 2.000% senior notes due 2026.  Amgen is a global biotechnology company that discovers, develops, manufactures and markets human therapeutics based on advances in cellular and molecular biology.

The Team